Imugene Limited
IUGNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | 149.5% | 140.6% | -138.4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -672.7% | -3,961% | 2,180.7% | -1,067.9% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -659% | -3,842.5% | 2,613.5% | -851.7% |
| EPS | -0.094 | -0.22 | -0.38 | -0.34 |
| % Growth | 57.2% | 42.1% | -11.8% | – |
| EPS Diluted | -0.094 | -0.22 | -0.38 | -0.34 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -602.3% | -3,857.1% | 2,495.3% | -857.1% |